OAM
VRTX icon

Occidental Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Occidental Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-738
Closed -$358K – 282
2025
Q1 		$358K Buy
+738
New +$344K 0.05% 166
2024
Q4 		– Sell
-695
Closed -$323K – 231
2024
Q3 		$323K Buy
695
+237
+52% +$114K 0.05% 167
2024
Q2 		$215K Buy
+458
New +$199K 0.04% 188

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Occidental Asset Management's VRTX Position: Q2 2025 in Review

Occidental Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 738 shares — an estimated $358K sold.

Occidental Asset Management first reported a position in VRTX in Q2 2024 and held it in 3 quarters. The position peaked at $358K in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Occidental Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Occidental Asset Management sold 738 Vertex Pharmaceuticals shares in Q2 2025, an estimated $358K.
  • Occidental Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Occidental Asset Management's Vertex Pharmaceuticals position peaked at $358K in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Occidental Asset Management's 13F filing for Q2 2025, filed 14 Jul 2025.